Gavin Churchyard
Overview
Explore the profile of Gavin Churchyard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
3765
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borges A, Russell M, Tait D, Scriba T, Nemes E, Skallerup P, et al.
Lancet Infect Dis
. 2025 Mar;
PMID: 40056922
Background: People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase 1 and 2 studies,...
2.
Mapamba D, Sabi I, Lalashowi J, Sauli E, Buza J, Olomi W, et al.
J Infect
. 2025 Jan;
90(2):106379.
PMID: 39756697
Background: Half the global tuberculosis health burden is due to post-tuberculosis lung disease. Host-directed therapies have been proposed to reduce this burden. N-acetylcysteine (NAC) provides the conditionally essential amino acid...
3.
Chihota V, Gombe M, Gupta A, Salazar-Austin N, Ryckman T, Hoffmann C, et al.
Drugs
. 2024 Dec;
85(2):127-147.
PMID: 39733063
Tuberculosis (TB) is the leading cause of death from a single infectious agent. The burden is highest in some low- and middle-income countries. One-quarter of the world's population is estimated...
4.
Pelzer P, Stuck L, Martinez L, Richards A, Acuna-Villaorduna C, Aronson N, et al.
Lancet Microbe
. 2024 Dec;
6(2):100961.
PMID: 39709975
Background: Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the protection against disease would accelerate tuberculosis vaccine development....
5.
Sumner T, Clark R, Prys-Jones T, Bakker R, Churchyard G, White R
AIDS
. 2024 Oct;
39(2):175-183.
PMID: 39411889
Background: People with HIV (PWH) are at an increased risk of tuberculosis (TB). New TB vaccines may help reduce this burden. New TB vaccine candidates are well tolerated and immunogenic...
6.
Salazar-Austin N, Bergman A, Mulder C, Tudor C, Mulatu F, Conradie G, et al.
BMC Health Serv Res
. 2024 Sep;
24(1):1043.
PMID: 39252005
Background: Tuberculosis (TB) preventive treatment (TPT) is a long-standing recommendation for children exposed to TB but remains poorly implemented. Home-based contact management may increase access and coverage of TPT among...
7.
Wallis R, Sabi I, Lalashowi J, Bakuli A, Mapamba D, Olomi W, et al.
NEJM Evid
. 2024 Aug;
3(9):EVIDoa2300332.
PMID: 39189858
Background: Tuberculosis remains a global health concern, and half of cured patients have permanent lung injury. N-acetylcysteine (NAC) has shown beneficial antimicrobial, antioxidant, and immunomodulatory effects in preclinical tuberculosis models....
8.
Lienhardt C, Dooley K, Nahid P, Wells C, Ryckman T, Kendall E, et al.
Bull World Health Organ
. 2024 Jul;
102(8):600-607.
PMID: 39070602
Simpler, shorter, safer and more effective treatments for tuberculosis that are easily accessible to all people with tuberculosis are desperately needed. In 2016, the World Health Organization (WHO) developed target...
9.
Matteelli A, Churchyard G, Cirillo D, den Boon S, Falzon D, Hamada Y, et al.
PLOS Glob Public Health
. 2024 Jul;
4(7):e0003306.
PMID: 38954723
The provision of tuberculosis preventive treatment is one of the critical interventions to reduce tuberculosis incidence and ultimately eliminate the disease, yet we still miss appropriate tools for an impactful...
10.
Churchyard G, Salazar-Austin N
Lancet Respir Med
. 2024 May;
12(8):582-583.
PMID: 38734021
No abstract available.